Eversept Partners LP Has $36.92 Million Stock Holdings in Bruker Corporation $BRKR

Eversept Partners LP boosted its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 14.1% in the fourth quarter, Holdings Channel reports. The firm owned 783,789 shares of the medical research company’s stock after purchasing an additional 96,660 shares during the quarter. Bruker comprises about 1.9% of Eversept Partners LP’s portfolio, making the stock its 14th biggest holding. Eversept Partners LP’s holdings in Bruker were worth $36,924,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in BRKR. Orbis Allan Gray Ltd bought a new position in Bruker during the second quarter worth about $192,735,000. Price T Rowe Associates Inc. MD lifted its stake in Bruker by 2,963.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,366,520 shares of the medical research company’s stock worth $111,488,000 after purchasing an additional 2,289,269 shares during the period. AQR Capital Management LLC lifted its stake in Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after purchasing an additional 1,850,215 shares during the period. Franklin Resources Inc. lifted its stake in Bruker by 317.7% during the fourth quarter. Franklin Resources Inc. now owns 2,309,404 shares of the medical research company’s stock worth $108,796,000 after purchasing an additional 1,756,460 shares during the period. Finally, Marshall Wace LLP bought a new position in Bruker during the fourth quarter worth about $51,530,000. Institutional investors own 79.52% of the company’s stock.

Bruker Price Performance

Bruker stock opened at $54.73 on Thursday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. The firm has a market cap of $8.33 billion, a P/E ratio of -228.04, a P/E/G ratio of 1.79 and a beta of 1.31. The business’s fifty day moving average is $45.75 and its two-hundred day moving average is $43.98. Bruker Corporation has a 52 week low of $28.53 and a 52 week high of $64.54.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. The company had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The business’s revenue was up 2.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities research analysts forecast that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, June 22nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. Bruker’s payout ratio is currently -83.33%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BRKR. Guggenheim cut their price target on shares of Bruker from $58.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, March 30th. JPMorgan Chase & Co. raised their price target on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. Weiss Ratings upgraded shares of Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Barclays raised their price target on shares of Bruker from $45.00 to $53.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Stifel Nicolaus set a $45.00 price target on shares of Bruker in a research note on Friday, May 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Bruker presently has a consensus rating of “Hold” and a consensus price target of $51.31.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the business’s stock in a transaction on Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the transaction, the vice president owned 128,443 shares of the company’s stock, valued at approximately $5,124,875.70. The trade was a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 27.20% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.